Table 1.
Clinical and pathological characteristics of patients with early and without relapse after curative liver resection for intrahepatic cholangiocarcinoma (n = 299).
| Clinicopathological indexes | No. (%) | ||||
|---|---|---|---|---|---|
| Total (N = 299) | Early Relapse (N = 168) | Without Relapse (N = 131) | P-value | ||
| Age (year) | ≤50 | 75 (25.1) | 41 (24.4) | 34 (26.0) | 0.759 |
| >50 | 224 (74.9) | 127 (75.6) | 97 (74.0) | ||
| Sex | Female | 118 (39.5) | 64 (38.1) | 54 (41.2) | 0.583 |
| Male | 181 (60.5) | 104 (61.9) | 77 (58.8) | ||
| HBsAg | Negative | 178 (59.5) | 101 (60.1) | 77 (58.8) | 0.815 |
| Positive | 121 (40.5) | 67 (39.9) | 54 (41.2) | ||
| HCV | Negative | 297 (99.3) | 167 (99.4) | 130 (99.2) | 1* |
| Positive | 2 (0.7) | 1 (0.6) | 1 (0.8) | ||
| AFP (ng/ml) | ≤20 | 264 (88.3) | 150 (89.3) | 114 (87.0) | 0.546 |
| >20 | 35 (11.7) | 18 (10.7) | 17 (13.0) | ||
| Child-Pugh | A | 289 (96.7) | 164 (97.6) | 125 (95.4) | 0.343 |
| B or C | 10 (3.3) | 4 (2.4) | 6 (4.6) | ||
| Liver cirrhosis | No | 218 (72.9) | 119 (70.8) | 99 (75.6) | 0.360 |
| Yes | 81 (27.1) | 49 (29.2) | 32 (24.4) | ||
| Tumor size (cm) | ≤5 | 131 (43.8) | 67 (39.9) | 64 (48.9) | 0.121 |
| >5 | 168 (56.2) | 101 (60.1) | 67 (51.1) | ||
| Tumor number | Single | 229 (76.6) | 120 (71.4) | 109 (83.2) | 0.017 |
| Multiple | 70 (23.4) | 48 (28.6) | 22 (16.8) | ||
| Lymphonodus node metastasis | Yes | 55 (18.4) | 42 (25.0) | 13 (10.0) | 0.001 |
| No | 244 (81.6) | 126 (75.0) | 118 (90.0) | ||
| Microvascular invasion | Yes | 42 (14.0) | 30 (17.9) | 12 (9.2) | 0.032 |
| No | 257 (86.0) | 138 (82.1) | 119 (90.8) | ||
| Tumor differentiationa | Poor | 66 (22.1) | 36 (21.4) | 30 (22.9) | 0.550 |
| Moderated | 184 (61.5) | 101 (60.1) | 83 (63.4) | ||
| Well | 49 (16.4) | 31 (18.5) | 18 (13.7) | ||
| TNM stageb | I + II | 226 (75.6) | 116 (69.0) | 110 (84.0) | 0.003 |
| III + IVA | 73 (24.4) | 52 (31.0) | 21 (16.0) | ||
| NLR | Low | 135 (45.2) | 70 (41.7) | 65 (49.6) | 0.170 |
| High | 164 (54.8) | 98 (58.3) | 66 (50.4) | ||
| PLR | Low | 156 (52.2) | 82 (48.8) | 74 (56.5) | 0.187 |
| High | 143 (47.8) | 86 (51.2) | 57 (43.5) | ||
| LMR | Low | 195 (65.2) | 115 (68.5) | 80 (61.1) | 0.184 |
| High | 104 (34.8) | 53 (31.5) | 51 (38.9) | ||
| CA19-9, U/ml | ≤89 | 190 (63.5) | 96 (57.1) | 94 (71.8) | 0.009 |
| >89 | 109 (36.5) | 72 (42.9) | 37 (28.2) | ||
Boldface type indicates significant values.
AFP, alpha-fetoprotein; CA19-9, carbohydrate antigen 19-9; HBsAg, hepatitis B surface antigen; HCV, hepatitis C virus; PLR, platelet-to-lymphocyte ratio; LMR, lymphocyte-to-monocyte ratio; NLR, neutrophil-to-lymphocyte ratio; TNM, tumor-node-metastasis; P, poor differentiation; M, moderated differentiation; W, well-differentiation.
Tumor differentiation was determined according to the “British Society of Gastroenterology guidelines on the management of cholangiocarcinoma”.
TNM stage: American Joint Committee on Cancer 7th edition staging for intrahepatic cholangiocarcinoma.
Fisher's exact tests; chi-square tests for all other analyses.